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Introduction Objectives 
MicroRNAs or miRNAs are non-coding small RNA molecules 
of about 19-24 nucleotides that function as post-transcriptional 
regulators of gene expression. They participate in many 
physiological and pathological processes ranging from 
embryonic development to neoplastic progression. 
• To define what microRNAs are and their functions.  
• To describe the role of microRNAs in different diseases. 
• To describe the role of microRNAs in diagnosis and 
treatment in veterinary neurology, focusing on dogs. 
Figure 1. Overview of miRNA biogenesis pathway (Lin and Gregory 2015). 
• miRNAs are involved in a wide variety of processes and diseases.  
• They offer a great potential as biomarkers for the diagnosis of neurological diseases having already been related to certain diseases. The 
therapeutic potential is clear, but many challenges remain such as crossing the blood-brain barrier and avoiding possible side effects. 
• This is a fairly new field in veterinary medicine and should therefore be more deeply studied and researched to reach the point where it 
can be applied to the daily practice.     
Conclusions 
Figure 2. Types of vectors used for miRNA delivery (Modified from Fu et al. 2019). 
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Table 1. Main studies of miRNAs in veterinary neurology 
Marioni-Henry 
et al. (2018) 
Seven miRNAs were consistently expressed in dogs with 
neurological disorders one of which highly related to the 
neoplastic group.  
Vansteenkiste et 
al. (2019) 
Two miRNAs had increased expression levels in the CSF 
and six miRNAs had decreased expression levels in dogs 
with Wobbler syndrome. It represents an initial 
characterization of the miRNA profile of normal canine 
CSF. 
Cirera et al. 
(2019) 
Failed to reproduce consistent results in CSF samples due 
to several reasons. 
Nakata et al. 
(2019) 
Plasma miR-26b is a potential novel diagnostic biomarker 
of degenerative myelopathy (DM).  
Narita et al. 
(2020) 
miR-15b and miR-342-3p have potential as noninvasive 
biomarkers for differentiating glioma from other 
intracranial diseases in dogs.  
